Analyst Expectations for Q2 Holdings’s Future
Over the past 3 months, 8 analysts have published their opinion on Q2 Holdings (NYSE:QTWO) stock. These analysts…
Analyst Ratings for GitLab
Analysts have provided the following ratings for GitLab (NASDAQ:GTLB) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
GitLab Gets Price Targets Cuts By Analysts Following Weak Revenue Outlook
GitLab Inc (NASDAQ: GTLB) reported a narrower-than-expected quarterly loss, but issued weak revenue guidance.
Wall Street’s Most Accurate Analysts Say Hold These 3 Tech Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Janney Montgomery Scott Initiates Coverage On Community Bank System with Buy Rating, Announces Price Target of $66
Janney Montgomery Scott analyst Jake Civiello initiates coverage on Community Bank System (NYSE:CBU) with a Buy rating and announces Price Target of $66.
Truist Securities Maintains Buy on Wendy’s, Raises Price Target to $28
Truist Securities analyst Jake Bartlett maintains Wendy's (NASDAQ:WEN) with a Buy and raises the price target from $27 to $28.
Benchmark Maintains Buy on Getty Images Holdings, Lowers Price Target to $7
Benchmark analyst Mark Zgutowicz maintains Getty Images Holdings (NYSE:GETY) with a Buy and lowers the price target from $9 to $7.
Oppenheimer Maintains Outperform on Seagen, Raises Price Target to $229
Oppenheimer analyst Jay Olson maintains Seagen (NASDAQ:SGEN) with a Outperform and raises the price target from $210 to $229.
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $20
Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $19 to $20.
Stephens & Co. Reiterates Overweight on Avid Bioservices, Maintains $22 Price Target
Stephens & Co. analyst Jacob Johnson reiterates Avid Bioservices (NASDAQ:CDMO) with a Overweight and maintains $22 price target.